Answers are grounded in this paper and cite their sources.
Review examines treatment recommendations for bone metastases in neuroendocrine tumours, suggesting a need for more evidence.
The role of anti‐resorptive agents in patients with bone metastases from neuroendocrine neoplasms is unclear. Our aim was to review bone‐specific treatment recommendations by the New Zealand National Neuroendocrine Tumour Multidisciplinary Meeting (MDM). Recommendations for bone‐specific treatment were given at 29/365 MDMs (7.9%); 44.8% were confirmed to have received the recommended therapy. Bone‐specific treatment recommendations were infrequent; there is a need for more data on the role of anti‐resorptive agents in this group.
No takes yet. Share an insight, caveat, or question.
Radley et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: